Nurix Therapeutics NRIX 深 沪
已收盘 08-15 16:00:00 美东时间
10.58
+0.020
+0.19%
华盛通- 最 高10.775
- 今 开10.64
- 成交量 50.22万股
- 最 低 10.43
- 昨 收 10.56
- 总市值 8.09亿
- 52周最高 29.56
- 市盈率 静 --
- 换手率 0.66%
- 52周最低 8.18
- 委 比 15.91%
- 总股本 7644.94万
- 历史最高 52.38
- 量 比 0.91
- 振 幅 3.27%
- 历史最低 4.22
- 每 手 1
- 风险率 5.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多智翔金泰GR1802注射液启动过敏性鼻炎适应症III期临床试验
GENRIX BIO 8月13日，智翔金泰（股票代码：688443）发布公告，公司自主研发的GR1802注射液针对过敏性鼻炎适应症的II期临床试验已达到主要疗效...
08-13 17:05
6 Analysts Assess Nurix Therapeutics: What You Need To Know
6 analysts have expressed a variety of opinions on Nurix Therapeutics (NASDAQ:N...
08-01 05:00
美股大行评级 | 巴克莱上调 Robinhood目标价至102美元；瑞银下调京东目标价从58美元至50美元
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从25美元升至29美元；摩根士丹利：维持Legend Biotech"超配"评级，目标价从80美元升至81美元
07-11 09:04
美股盘前丨三大股指期货盘前涨跌不一 达美航空涨超13%
【时政新闻】 美国上周初请失业金人数22.7万人，前值23.3万人； 商务部：中美双方在多个层级就经贸领域各自关切保持密切沟通； 外交部：美对铜加征关税不符合任...
07-10 20:33
Nurix Therapeutics Q2 EPS $(0.52) Beats $(0.75) Estimate, Sales $44.056M Beat $17.009M Estimate
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.75) by 30.76 percent. This is a 26.76 percent increase over losses of $(0.71) per share
07-10 04:02
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Nurix Therapeutics reported strong financial results for Q2 2025, including $44.1M revenue and $485.8M in cash and marketable securities. Key milestones include positive data for bexobrutideg in CLL and WM, Sanofi extending its STAT6 collaboration with a $15M fee, and FDA clearance for GS-6791/NX-0479's IND. Nurix's pipeline advancements highlight its focus on targeted protein degradation therapies for cancer and inflammatory diseases.
07-09 20:01
European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia
EMA grants Orphan Drug Designation to bexobrutideg (NX-5948) for treating lymphoplasmacytic lymphoma. The drug, a BTK degrader, has also received EMA PRIME and FDA Fast Track designations for CLL/SLL. Bexobrutideg is in Phase 1a/b trials for B-cell malignancies. The designation offers incentives for rare disease treatments, emphasizing unmet needs in Waldenström macroglobulinemia.
07-07 11:00
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nurix Therapeutics announced on June 10, 2025, that it granted inducement awards to 17 new employees under its 2024 Equity Inducement Plan. The awards include stock options for 97,400 shares and restricted stock units (RSUs) for 66,750 shares. Stock options vest over four years, with 1/4 vesting after the first year and 1/48 each month thereafter. RSUs vest with 1/4 after one year and 1/16 quarterly thereafter. The options have a 10-year term wit...
06-13 20:01
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)
Nurix Therapeutics announced positive clinical data for bexobrutideg in treating relapsed or refractory B-cell malignancies, with an 80.9% objective response rate in chronic lymphocytic leukemia (CLL) and 84.2% in Waldenström macroglobulinemia (WM), showing deepening responses over time. The drug demonstrated favorable safety profiles with no new safety signals observed at higher doses or longer durations. Nurix plans to initiate pivotal trials f...
06-12 11:00
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)
Nurix Therapeutics will host a webcast on June 12, 2025, to discuss new data from the Phase 1 trial of bexobrutideg (NX-5948), a BTK degrader, to be presented at the European Hematology Association Congress in Milan. The data will highlight updated findings in relapsed/refractory CLL and Waldenström macroglobulinemia. The webcast will be available live on the company’s website and archived for 30 days.
06-06 11:00
